CORT - Corcept Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

3.22B

Cash

410.8M

Avg Qtr Burn

N/A

Short % of Float

26.76%

Insider Ownership

11.39%

Institutional Own.

91.74%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Korlym® (Relacorilant) Details Hypercortisolism, Cushing’s syndrome	Phase 4 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Korlym® (Relacorilant) Details Hypercortisolism	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Korlym® (Relacorilant) Details Hypercortisolism, Cushing’s syndrome	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Relacorilant + Nab-paclitaxel Details Ovarian cancer, Cancer, Solid tumor/s	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Miricorilant Details Non-alcoholic steatohepatitis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Relacorilant (GR antagonist) + Enzalutamide Details Cancer, Castration-resistant prostate cancer, Solid tumor/s, Prostate cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Dazucorilant Details Amyotrophic lateral sclerosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Miricorilant Details Obesity, Antipsychotic-Induced Weight Gain	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Relacorilant + pembrolizumab Details Cancer, Adrenal cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Relacorilant + Nab-paclitaxel Details Pancreatic cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.